论文部分内容阅读
目的:探讨绞股蓝皂苷对非酒精性脂肪肝患者肝纤维化及肝功能的影响。方法:将180例非酒精性脂肪性肝病患者根据随机抽签原则分为治疗组与对照组各90例,对照组给予肝得健治疗,治疗组在此基础上加用绞股蓝皂苷辅助治疗,治疗周期为1个月。结果:治疗组总显效率为94.4%,对照组总显效率为77.8%,治疗组总显效率明显高于对照组,差异有统计学意义(P<0.05)。两组治疗后的血清ALT、AST、GGT、HA、LN和C-Ⅳ值均明显低于治疗前,差异有统计学意义(P<0.05);治疗后治疗组的ALT、AST、HA、LN和C-Ⅳ值均明显低于对照组,差异有统计学意义(P<0.05);治疗后治疗组的恶心、疼痛、食欲不振、肝脾肿大评分均明显低于对照组(P<0.05)。结论:绞股蓝皂苷辅助治疗非酒精性脂肪性肝病能有效降低肝功能恶化与肝纤维化趋势,缓解临床症状,从而提高总体预后。
Objective: To investigate the effects of gypenosides on hepatic fibrosis and liver function in patients with non-alcoholic fatty liver disease. Methods: 180 patients with nonalcoholic fatty liver disease were randomly divided into treatment group and control group according to the principle of random sampling. 90 patients in the control group were given Gandejian. On the basis of this, the treatment group was treated with Gypenosides, and the treatment period For 1 month. Results: The total effective rate was 94.4% in the treatment group and 77.8% in the control group. The total effective rate in the treatment group was significantly higher than that in the control group (P <0.05). The serum ALT, AST, GGT, HA, LN and C-IV after treatment in both groups were significantly lower than those before treatment (P <0.05). After treatment, the levels of ALT, AST, (P <0.05). The scores of nausea, pain, loss of appetite and hepatosplenomegaly in the treatment group were significantly lower than those in the control group (P <0.05) ). Conclusion: Gypenosides adjuvant treatment of non-alcoholic fatty liver disease can effectively reduce the deterioration of liver function and liver fibrosis, relieve clinical symptoms, thereby improving the overall prognosis.